Anaemia overview and treatment
Date added: 17-06-26
Category: Statistics Essay
Anaemia is a syndrome characterised by a lack of healthy red blood cells or haemoglobin deficiency in the red blood cells, resulting in inadequate oxygen supply to the tissues. The condition can be temporary, long-term or chronic, and of mild to severe intensity. There are many forms and causes of anaemia. Normal blood consists of three types of blood cells: white blood cells (leucocytes), platelets and red blood cells (erythrocytes). The first generation of erythrocyte precursors in the developing foetus are produced in the yolk sac. They are carried to the developing liver by the blood where they form mature red blood cells that are required to meet the metabolic needs of the foetus. Until the 18th week of gestation, erythrocytes are produced only by liver after which the production shifts to the spleen and the bone marrow. The life of a red blood cell is about 127 days or 4 months (Shemin and Rittenberg, 1946; Kohgo et al., 2008). The main causes of anaemia are blood loss, production of too few red blood cells by the bone marrow or a rapid destruction of cells.
Haemoglobin, a protein, present in the red blood cells is involved in the transport of oxygen from the lungs to all the other organs and tissues of the body. Iron is an important constituent of the haemoglobin protein structure which is intimately involved in the transport of oxygen. Anaemia is generally defined as a lower than normal haemoglobin concentration. The normal blood haemoglobin concentration is dependent on age and sex, and, according to the World Health Organisation (WHO) Expert Committee Report, anaemia results when the blood concentration of haemoglobin falls below 130 g/L in men or 120 g/L in non-pregnant women (WHO, 1968). However, the reference range of haemoglobin concentration in blood could vary depending on the ethnicity, age, sex, environmental conditions and food habits of the population analysed. According to Beutler and Warren (2006), more reasonable benchmarks for anaemia are 137 g/L for white men aged between 20 and 60 years and 132 g/L for older men. The value for women of all ages would be 122 g/L. Also, the lower limit of normal of haemoglobin concentrations of African Americans are appreciably lower than that of Caucasians (Beutler and Warren, 2006).
Besides the well recognised iron deficiency anaemia, several inherited anaemias are also known. These are mostly haemoglobinopathies. Adult haemoglobin is a tetrameric haeme-protein. Abnormalities of beta-chain or alpha-chain produce the various medically significant haemoglobinopathies. The variations in amino acid composition induced genetically impart marked differences in the oxygen carrying properties of haemoglobin. Mutations in the haemoglobin genes cause disorders that are qualitative abnormalities in the synthesis of haemoglobin (e.g., sickle cell disease) and some that are quantitative abnormalities that pertain to the rate of haemoglobin synthesis (e.g., the thalassemias) (Weatherall., 1969). In SCD, the missense mutation in the Î²-globin gene causes the disorder. The mutation causing sickle cell anemia is a single nucleotide substitution (A to T) in the codon for amino acid 6. The substitution converts a glutamic acid codon (GAG) to a valine codon (GTG). The form of haemoglobin in persons with sickle cell anemia is referred to as HbS. Also, the valine for glutamic acid replacement causes the haemoglobin tetramers to aggregate into arrays upon deoxygenation in the tissues. This aggregation leads to deformation of the red blood cell making it relatively inflexible and restrict its movement in the capillary beds. Repeated cycles of oxygenation and deoxygenation lead to irreversible sickling and clogging of the fine capillaries. Incessant clogging of the capillary beds damages the kidneys, heart and lungs while the constant destruction of the sickled red blood cells triggers chronic anaemia and episodes of hyperbilirubinaemia.
Fanconi anaemia (FA) is an autosomal recessive condition, and the most common type of inherited bone marrow failure syndrome. The clinical features of FA are haematological with aplastic anaemia, myelodysplastic syndrome (MDS), and acute myeloid leukaemia (AML) being increasingly present in homozygotes (Tischkowitz and Hodgson, 2003). Cooley's anaemia is yet another disorder caused by a defect in haemoglobin synthesis.
Autoimmune haemolytic anaemia is a syndrome in which individuals produce antibodies directed against one of their own erythrocyte membrane antigens. The condition results in diminished haemoglobin concentrations on account of shortened red blood cell lifespan (Sokol et al., 1992).
Megaloblastic anaemia is a blood disorder in which anaemia occurs with erythrocytes which are larger in size than normal. The disorder is usually associated with a deficiency of vitamin B12 or folic acid . It can also be caused by alcohol abuse, drugs that impact DNA such as anti-cancer drugs, leukaemia, and certain inherited disorders among others (Dugdale, 2008).
Malaria causes increased deformability of vivax-infected red blood cells (Anstey et al., 2009). Malarial anaemia occurs due to lysis of parasite-infected and non-parasitised erythroblasts as also by the effect of parasite products on erythropoiesis (Ru et al., 2009).
Large amounts of iron are needed for haemoglobin synthesis by erythroblasts in the bone marrow. Transferrin receptor 1 (TfR1) expressed highly in erythroblasts plays an important role in extracellular iron uptake (Kohgo et al., 2008). Inside the erythroblasts, iron transported into the mitochondria gets incorporated into the haeme ring in a multistep pathway. Genetic abnormalities in this pathway cause the phenotype of ringed sideroblastic anemias (Fleming, 2002). The sideroblastic anemias are a heterogeneous group of acquired and inherited bone marrow disorders, characterised by mitochondrial iron overload in developing red blood cells. These conditions are diagnosed by the presence of pathologic iron deposits in erythroblast mitochondria (Bottomley, 2006). Â
2. Classification of anaemia
Anaemia can be generally classified based on the morphology of the red blood cells, the pathogenic spectra or clinical presentation (Chulilla et al., 2009). The morphological classification is based on mean corpuscular volume (MCV) and comprises of microcytic, macrocytic and normocytic anaemia.
(a) Microcytic anaemia refers to the presence of RBCs smaller than normal volume, the reduced MCV (< 82 fL) reflecting decreased haemoglobin synthesis.Â Thus, it is usually associated with hypochromic anaemia. Microcytic anaemia can result from defects either in iron acquisition or availability (Iolascon et al., 2009), or disorders of haeme metabolism or globin synthesis (Richardson, 2007). The differential diagnosis for microcytic anaemia includes iron deficiency anaemia (IDA), thalassaemia, anaemia of chronic disorders (ACD), and rarely sideroblastic anaemia (Chulilla et al., 2009). Microcytosis without anaemia is characteristic of thalassaemia trait. The red blood cell distribution width (RDW) obtained with haematological analysers provides the index of dispersion in the erythrocyte distribution curve and complements MCV values. RDW is helpful to differentiate between thalassaemia and IDA. RDW is normal in thalassemia; on the contrary, microcytic anemia with RDW > 15 would probably indicate IDA (Chulilla et al., 2009).
In macrocytic anaemia, erythrocytes are larger (MCV > 98 fL) than their normal volume (MCV = 82-98 fL). Vitamin B12 deficiency leads to delayed DNA synthesis in rapidly growing hematopoietic cells, and can result in macrocytic anemia. Drugs that interfere with nucleic acid metabolism, such as.hydroxyurea increases MCV (> 110 fL) while alcohol induces a moderate macrocytosis (100-110 fL). In the initial stage, most anaemias are normocytic. The causes of normocytic anaemia are nutritional deficiency, renal failure and haemolytic anemia (Tefferi, 2003). The most common normocytic anaemia in adults is anaemia of chronic disease (ACD) (Krantz, 1994). Common childhood normocytic anaemias are, besides iron deficiency anaemia, those due to acute bleeding, sickle cell anemia, red blood cell membrane disorders and current or recent infections especially in the very young (Bessman et al., 1983). Homozygous sickle cell disease is the most common cause of haemolytic normocytic anemias in children (Weatherall DJ, 1997a).
In practice, the morphological classification is quicker and therefore, more useful as a diagnostic tool. Besides, MCV is also closely linked to mean corpuscular haemoglobin (MCH), which denotes mean haemoglobin per erythrocyte expressed in picograms (Chulilla et al., 2009). Thus, MCV and MCH decrease simultaneously in microcytic, hypochromic anemia and increase together in macrocytic, hyperchromic anemia.
Pathogenic classification of anaemia is based on the production pattern of RBC: whether anaemia is due to inadequate production or loss of erythrocytes caused by bleeding or haemolysis. This approach is useful in those cases where MCV is normal. Pathogenic classification is also essential for proper recognition of the mechanisms involved in the genesis of anaemia. Based on the pathogenic mechanisms, anaemia is further divided into two types namely, (i) hypo-regenerative in which the bone marrow production of erythrocytes is decreased because of impaired function, decreased number of precursor cells, reduced bone marrow infiltration, or lack of nutrients; and (ii) regenerative: when bone marrow upregulates the production of erythrocytes in response to the low erythrocyte mass (Chulilla et al., 2009). This is typified by increased generation of erythropoietin in response to lowered haemoglobin concentration, and also reflects a loss of erythrocytes, due to bleeding or haemolysis. The reticulocyte count is typically higher.
Sickle cell disease is characterised by sickled red cells.Â The first report of SCD was published a century ago noting the presence of "peculiar elongated cells" in blood by James Herrick, an American physician (1910). Pauling et al. (1949) described it as a "molecular disease". The molecular nature of sickle haemoglobin (Hb S) in which valine is substituted for glutamic acid at the sixth amino acid position in the beta globin gene reduces the solubility of Hb, causing red cells to sickle (Fig. 1).
Sickling of cells occurs at first reversibly, then finally as a state of permanent distortion, when cells containing HbS and inadequate amounts of other haemoglobins including foetal haemoglobin, which retards sickling, become deoxygenated (Bunn, 1997). The abnormal red cells break down, leading to anaemia, and clog blood vessels with aggregates, leading to recurrent episodes of severe pain and multiorgan ischaemic damage (Creary et al., 2007). The high levels of inflammatory cytokines in SCD may promote retention of iron by macrophage/reticuloendothelial cells and/or renal cells. SCD care commonly depends on transfusion that results in iron overload (Walter et al., 2009).
3. Pathogenesis of anaemia
Anaemia is a symptom , or a syndrome, and not a disease (Chulilla et al., 2009). Several types of anaemia have been recognised, the pathogenesis of each being unique.
Iron deficiency anaemia (IDA) is the most common type of anaemia due to nutritional causes encountered worldwide (Killip et al., 2008). Iron is one of the essential micronutrients required for normal erythropoietic function While the causes of iron deficiency vary significantly depending on chronological age and gender, IDA can reduce work capacity in adults (Haas & Brownlie, 2001) and affect motor and mental development in children (Halterman et al., 2001). The metabolism of iron is uniquely controlled by absorption rather than excretion (Siah et al., 2006). Iron absorption typically occurring in the duodenum accounts for only 5 to 10 per cent of the amount ingested in homoeostatis. The value decreases further under conditions of iron overload, and increases up to fivefold under conditions of iron depletion (Killip et al., 2008). Iron is ingested as haem iron (10%) present in meat, and as non-haem ionic form iron (90%) found in plant and dairy products. In the absence of a regulated excretion of iron through the liver or kidneys, the only way iron is lost from the body is through bleeding and sloughing of cells. Thus, men and non-menstruating women lose about 1 mg of iron per day while menstruating women could normally lose up to 1.025 mg of iron per day (Killip et al., 2008). The requirements for erythropoiesisÂ which are typically 20-30 mg/dayÂ are dependent on the internal turnover of iron (Munoz et al., 2009) For example, the amount of iron required for daily production of 300 billion RBCs (20-30 mg) is provided mostly by recycling iron by macrophages (Andrews, 1999).
Iron deficiency occurs when the metabolic demand for iron exceeds the amount available for absorption through consumption. Deficiency of nutritional intake of iron is important, while abnormal iron absorption due to hereditary or acquired iron-refractory iron deficiency anemia (IRIDA) is another important cause of unexplained iron deficiency. However, IDA is commonly attributed to blood loss e.g., physiological losses in women of reproductive age. It might also represent occult bleeding from the gastrointestinal (GI) tract generally indicative of malignancy (Hershko and Skikne, 2009).
Iron absorption and loss play an important role in the pathogenesis and management of IDA. Human iron disorders are necessarily disorders of iron balance or iron distribution. Iron homeostasis involves accurate control of intestinal iron absorption, efficient utilisation of iron for erythropoiesis, proper recycling of iron from senescent erythrocytes, and regulated storage of iron by hepatocytes and macrophages (Andrews, 2008). Iron deficiency is largely acquired, resulting from blood loss (e.g., from intestinal parasitosis), from inadequate dietary iron intake, or both. Infections, for example, with H pylori, can lead to profound iron deficiency anemia without significant bleeding. Genetic defects can cause iron deficiency anaemia. Mutations in the genes encoding DMT1 (SLC11A2) and glutaredoxin 5 (GLRX5) lead to autosomal recessive hypochromic, microcytic anaemia (Mims et al., 2005). Transferrin is a protein that keeps iron nonreactive in the circulation, and delivers iron to cells possessing specific transferrin receptors such as TFR1 which is found in largest amounts on erythroid precursors. Mutations in the TF gene leading to deficiency of serum transferrin causes disruption in the transfer of iron to erythroid precursors thereby producing an enormous increase in intestinal iron absorption and consequent tissue iron deposition (Beutler et al., 2000).
Quigley et al. (2004) found a haem exporter, FLVCR, which appears to be necessary for normal erythroid development. Inactivation of FLVCR gene after birth in mice led to severe macrocytic anaemia, indicating haem export to be important for normal erythropoiesis.
The anaemia of chronic disease (ACD) found in patients with chronic infectious, inflammatory, and neoplastic disorders is the second most frequently encountered anaemia after iron-deficiency anaemia. It is most often a normochromic, normocytic anaemia that is primarily caused by an inadequate production of red cells, with low reticulocyte production (Krantz, 1994). The pathogenesis of ACD is unequivocally linked to increased production of the cytokines including tumour necrosis factor, interleukin-1, and the interferons that mediate the immune or inflammatory response. The various processes leading to the development of ACD such as reduced life span of red cells, diminished erythropoietin effect on anaemia, insufficient erythroid colony formation in response to erythropoietin, and impaired bioavailability of reticuloendothelial iron stores appear to be caused by inflammatory cytokines (Means, 1996;2003). Although iron metabolism is characteristically impaired in ACD, it may not play a key role in the pathogenesis of ACD (Spivak, 2002). Neither is the lack of available iron central to the pathogenesis of the syndrome, according to Spivak (2002), who found reduced iron absorption and decreased erythroblast transferrin-receptor expression to be the result of impaired erythropoietin production and inhibition of its activity by cytokines. However, reduced erythropoietin activity, mostly from reduced production, plays a pivotal role in the pathogenesis of ACD observed in systemic autoimmune diseases (Bertero and Caligaris-Cappio, 1997). Indeed, iron metabolism as well as nitric oxide (NO), which contributes to the regulation of iron cellular metabolism are involved in the pathogenesis of ACD in systemic autoimmune disorders. Inflammatory mediators, particularly the cytokines, are important factors involved in the pathogenesis of the anaemia of chronic disease, as seen in rheumatoid arthritis anaemia (Baer et al., 1990), the cytokines causing impairment of erythroid progenitor growth and haemoglobin production in developing erythrocytes.Â
Anaemia is also commonly found in cases of congestive heart failure (CHF), again caused by excessive cytokine production leading to reduced erythropoietin secretion, interference with erythropoietin activity in the bone marrow and reduced iron supply to the bone marrow (Silverberg et al., 2004). However, in the presence of chronic kidney insufficiency, abnormal erythropoietin production in the kidney plays a role in the pathogenesis of anaemia in CHF.
The myelodysplastic syndromes (MDS) are common haematological malignancies affecting mostly the elderly as age-related telomere shortening enhances genomic instability (Rosenfeld and List, 2000). Radiation, smoking and exposure to toxic compounds e.g., pesticides, organic chemicals and heavy metals, are factors promoting the onset of MDS via damage caused to progenitor cells, and, thereby, inducing immune suppression of progenitor cell growth and maturation. TNF- and other pro-apoptotic cytokines could play a central role in the impaired haematopoiesis of MDS (Rosenfeld and List, 2000). Premature intramedullary cell death brought about by excessive apoptosis is another important pathogenetic mechanism in MDS (Aul et al., 1998).Â
Sickle cell disease (SCD) arising from a point mutation in the Î²-globin gene and leading to the expression of haemoglobin S (HbS) is the most common monogenetic disorder worldwide. Chronic intravascular haemolysis and anaemia are some important characteristics of SCD. Intravascular haemolysis causes endothelial dysfunction marked by reduced nitric oxide (NO) bioavailability and NO resistance, leading to acute vasoconstriction and, subsequently, pulmonary hypertension (Gladwin and Kato, 2005). Â However, a feature that differentiates SCD from other chronic haemolytic syndromes is the persistent and intense inflammatory condition present in SCD. The primary pathogenetic event in SCD is the intracellular polymerisation or gelation of deoxygenated HbS leading to rigidity in erythrocytes (Wun, 2001). The deformation of erythrocytes containing HbS is dependent on the concentration of haemoglobin in the deoxy conformation (Rodgers et al., 1985). It has been demonstrated that sickle monocytes are activated which, in turn, activate endothelial cells and cause vascular inflammation. The vaso-occlusive processes in SCD involve inflammatory and adhesion molecules such as the cell adhesion molecules (CAM family), which play a role in the firm adhesion of reticulocytes and leukocytes to endothelial cells, and the selectins, which play a role in leukocyte and platelet rolling on the vascular wall (Connes et al., 2008). Thus, inflammation, leucocyte adhesion to vascular endothelium, and subsequent endothelial injury are other crucial factors contributing to the pathogenesis of SCD (Jison et al., 2004).
4. Current therapies for clinical management of sickle cell diseaseincludingacritical appraisal of transfusion
Between 1973 and 2003, the average life expectancy of a patient with SCD increased dramatically from a mere 14 years to 50 years thanks to the development of comprehensive care models and painstaking research efforts in both basic sciences especially molecular and genetic studies, and clinical aspects of SCD (Claster and Vichinsky, 2003). The clinical manifestations of SCD are highly variable. Both the phenotypic expression and intensity of the syndrome are vastly different among patients and also vary "longitudinally" within the same patient (Ballas, 1998). New pathophysiological insights available have enabled treatments to be developed for the recognised haematologic and nonhaematologic abnormalities in SCD (Claster and Vichinsky, 2003). The main goals of SCD treatment are symptom alleviation, crises avoidance and effective management of disease complications. The strategy adopted is primarily palliative in nature, and consists of supportive, symptomatic and preventative approaches to therapy. Symptomatic management includes pain mitigation, management of vasoocclusive crisis, improving chronic haemolytic anaemia, treatment of organ failure associated with the disease, and detection and treatment of pulmonary hypertension (Distenfeld and Woermann, 2009). The preventative strategies include use of prophylactic antibiotics (e.g., penicillin) in children, prophylactic blood transfusion for prevention of stroke in patients especially young children who are at a very high risk of stroke, and treatment with hydroxyurea of patients experiencing frequent acute painful episodes (Ballas, 2002). Currently, curative therapy for sickle cell anaemia is only available through bone marrow and stem cell transplantation. Hematopoietic cell transplantation using stem cells from a matched sibling donor has yielded excellent results in paediatric patients (Krishnamurti, 2007). Curative gene therapy is still at the exploratory stage (Ballas, 2002).
Current and potential therapies
The potential treatment strategies basically target cellular dehydration, sickle haemoglobin concentrations, endothelial dysfunction, and abnormal coagulation regulation (Claster and Vichinsky, 2003). HbS concentrations are essentially tackled through transfusions while approaches to reduce HbS polymerisation which is the main mechanism for the development of vaso-occlusion include (a) increasing foetal haemoglobin (HbF) concentration using hydroxyurea (Fig. 2), butyrate, or erythropoietin, and (b) preventing sickle cell dehydration using Clotrimazole (Fig. 3) or Mg2+pidolate. Hydroxyurea therapy increases the production of HbF in patients with sickle cell anaemia, and, thereby, inhibits the polymerisation of HbS and alleviates both the haemolytic and vaso-occlusive manifestations of the disease (Goldberg et al., 1990). Recombinant erythropoietin also increases the number of reticulocytes with HbF. Additionally, it has been observed that administration of intravenous recombinant erythropoietin with iron supplementation alternating with hydroxyurea enhances HbF levels more than hydroxyurea alone (Rodgers et al., 1993). As SCD is essentially characterized by an abnormal state of endothelial cell activationÂ that is, a state of inflammation, a pharmacologic approach to inhibit endothelial cell activation has proved clinically beneficial (Hebbel and Vercellotti, 1997). Thus, administration of sulfasalazine which is a powerful inhibitor of activation of nuclear factor (NF)-B, the transcription factor promoting expression of genes for a number of pro-adhesive and procoagulant molecules on endothelium to humans has been found to provide transcriptional regulation of SCD at the endothelium level (Solovey et al., 2001).
Red blood cell transfusion : a critical appraisal
A key therapy that is applied regularly in the clinical management of patients with SCD is packed red blood cell transfusion. RBC transfusion improves the oxygen-carrying capacity which is achieved by enhancing the haemoglobin levels, causes dilution of HbS concentration thereby, reducing blood viscosity and boosting oxygen saturation. Furthermore, RBC transfusion is helpful in suppressing endogenous production of sickle RBCs by augmenting tissue oxygenation ( Josephson et al., 2007). There are two major types of RBC transfusion therapy: intermittent and chronic which are further classified as prophylactic or therapeutic. Intermittent transfusions are generally therapeutic in nature and administered to control acute manifestations of SCD whereas chronic transfusions are performed as general preventative measures to check complications of SCD. RBC transfusion given as a single dose is termed as simple transfusion. Exchange transfusion involves administration of a larger volume of RBCs replacing the patient's RBCs that are simultaneously removed. Details of the various types of RBC transfusion and the major clinical indications for the same in SCD patients are listed in Table 1.
SCD (Source: Josephson et al., 2007)
Indications for Intermittent transfusions
Indications for intermittent transfusions include acute manifestations of SCD, as indicated in Table 1, that require redressal through therapeutic transfusions. However, under certain circumstances intermittent transfusions could be prophylactic such as for instance, when SCD patients are transfused before specific surgeries viz., those related to pregnancy complications or renal failure (Table 1).
Acute Chest Syndrome (ACS) describes a manifestation of SCD in which, due to sickling, infectious and noninfectious pulmonary events are complicated, resulting in a more severe clinical course. The diagnosis is the presence of a new infiltrate on chest radiography that is accompanied by acute respiratory symptoms. ACD accounts for nearly 25% of all deaths from SCD (Vichinsky, 2002). Repeated episodes of ACS are associated with an increased risk of chronic lung disease and pulmonary hypertension (Castro, 1996). The severe pulmonary events occurring in SCD may be precipitated by any trigger of hypoxia (Vichinsky, 2002). Transfusions are very efficacious and provide immediate benefit by reversing hypoxia in ACS. Transfusion of leucocyte-poor packed red cells matched for Rh, C, E, and Kell antigens can curtail antibody formation to below 1% (Vichinsky, 2002). Simple transfusions suffice for less severe cases; however, exchange transfusion is recommended to minimise the risk of increased viscosity. Also, chronic transfusion appears promising for prevention of recurrence in selected patients (Styles and Vichinsky, 1994). In a multicentre ACS trial, prophylactic transfusion was found to almost completely eliminate the risk of pulmonary complications (Vichinsky, 2002).
Acute Symptomatic Anaemia arises in SCD as a result of blood loss, increased RBC destruction, suppression of erythropoiesis etc. and is effectively treated with intermittent transfusion of RBCs to relieve symptoms of cardiac and respiratory distress (Josephson et al., 2007).
Aplastic Anaemia is commonly caused in SCD on account of infection of haematopoietic precursors in the bone marrow by Parvovirus B19 leading to a steep fall in RBCs. According to Josephson et al. (2007), therapeutic intermittent transfusion of RBCs is again the recommended first-line of treatment to improve total haemoglobin count and prevent cardiac decompensation. However, in those patients who are prone to fluid overload on account of cardiac or renal dysfunction an alternative transfusion strategy is to remove the whole blood and replace it with packed cells while avoiding the addition of excess volume (Josephson et al., 2007).
Acute Stroke is a high risk especially in paediatric SCD cases because of elevated cerebral flow. Enormous decline in stroke rate have occurred in children receiving intermittent simple transfusion (Adams et al., 1998). However, the identification of the stroke type would be necessary in all SCD patients in order to determine the appropriate treatment approach since the occurrence of infarctive strokes is higher in children as opposed to a higher incidence of haemorrhagic strokes in adults (Adams, 2003).
Indications for Chronic Transfusions
Prophylactic chronic RBC transfusion every 3 to 4 weeks to maintain HbS levels lower than 30% is crucial for preventing first as well as recurrent strokes in children (Johnson et al., 2007). The transfusions could either be chronic simple transfusion or prophylactic chronic RBC exchange transfusion. Prophylactic chronic transfusions are recommended for patients with chronic renal failure so as to avoid severe symptomatic anaemia and for those patients with SCD undergoing pregnancy with complications. However, prophylactic transfusion is not indicated for SCD patients with normal pregnancy (Tuck et al., 1987).
Controversial and indeterminate indications for intermittent or chronic transfusion
According to Hankins et al. (2005), chronic transfusion therapy is helpful in reducing the incidence of strokes in children but not the severity of strokes. In the case of acute priapism, improvement in patients has been observed after exchange or simple transfusion (RifikindÂ et al., 1979). Yet, due to the ASPEN syndrome, transfusion currently is only a second-line therapy in the management of priapism ( Miller et al., 1995).
RBC transfusion is a vital component in the management of symptoms and complications of SCD. It has drastically reduced the morbidity and mortality of SCD. Yet, immune-related effects such as FNHTRs and alloimmunisation to HLAs,Â and nonimmune-related effects e.g., iron overload and transfusion-transmitted infections are serious adverse effects of the transfusion therapy that need to be attended to in SCD patients receiving transfusion (Johnson et al., 2007). Chronic transfusions could result in an inexorable accumulation of tissue iron that could become fatal if not treated (Cohen, 1987). Excess iron damages the liver, endocrine organs, and heart and may be fatal by adolescence (Engle, 1964).
5. Critical review of thalassemias : (i) Molecular pathogenesis
The large number of inherited haemoglobin disorders known today include (a) those related to anomalies in the haemoglobin structure e.g., sickle cell disease, and (b) the thalassemias whose hallmark is globin-chain deficiency of one or other of the globin chains of adult haemoglobin in erythroid cells.
These are a set of genetic disorders inherited as simple codominant traits affecting haemoglobin synthesis. Depending on the haemoglobin chain affected, 2 types of thalassemia are recognised: Î±-thalassaemia and Î²-thalassaemia. Homozygous Î²-thalassaemia is marked by a quantitative deficiency of the Î²-globin chains in the erythroid cells. A complete absence of the Î²-globin chains occurs in homozygous Î²o-thalassaemia whereas in homozygous Î²+-thalassaemia the Î²-globin chains are present at less than 30% of normal. Accounting for nearly 90% of the cases, Î²+-thalassaemia is the most commonly observed form of Î²-thalassaemia. The condition is termed thalassaemia major when there is microcytic hypochromic anaemia with severe haemolysis, hepatosplenomegaly, skeletal deformities and iron overload. Î²-thalassaemia homozygotes exhibit severe transfusion-dependent anaemia in the very first year of life. Homozygotic individuals having a relatively benign clinical phenotype and surviving with or without transfusion are described as thalassaemia intermedia (Weatherall, 1969). The thalassaemias, thus, encompass a wide gamut of clinical disability from intrauterine death to a mild anaemia with no overt symptoms (Weatherall, 1997b). The coexistence ofÂ Î± -thalassaemia leading to reduction in the synthesis of Î±-globin chains, and a genetic predisposition to produce high levels of HbF, could be important factors for the extensive phenotypic variability described above (Weatherall, 1996). The milder form of thalassaemia intermedia is the result of a lesser imbalance in globin chain synthesis probably the result of residual Î² -globin chain synthesis due to mild mutation or due to reduced synthesis of Î±-globin chains due to co-inheritance of Î±-thalassaemia (Nadkarni et al., 2001). Persons having the heterozygous form of the disorder are usually asymptomatic but can be recognised by typical abnormalities of red cell morphology (shown in Fig.4) and indices (Spritz and Forget, 1983). Compared to the heterozygous form of Î²-thalassaemia, a larger imbalance exists in the Î±- to Î²-globin chain synthesis in the homozygous Î²-thalassemia or Cooley anaemia. The excess Î±-globin chains are liable to precipitate, causing damage to the Î²-thalassemic red cell membrane and affecting erythropoiesis. Important manifestations of homozygous Î²-thalassemia are severe chronic microcytic haemolytic anaemia and hepatosplenomegaly due to extramedullary haematopoiesis (Spritz and Forget, 1983).
(Source: Weatherall, 1997b)
As many as 175-200 molecular mutations affecting the Î²-globin gene complex are involved in creating the Î²-thalassaemia syndromes with the resultant altered synthetic ratios of Î±- to Î²-globin chains, precipitation of excess unbalanced Î±-globin chains, and programmed cell death of erythroid precursors (Steinberg and Rodgers, 2001; Gambari, 2010). Hence, the pathogenetic basis of the clinical diversity of the Î²-thalassaemia syndromes essentially rests with the striking heterogeneity of mutations in the Î²-globin gene (Thein, 1993). The -158 (C Ã T) substitution in the GÎ³ gene has been found to be linked to the increase in HbF synthesis leading to less severe disease in thalassaemia intermedia (Gilman and Huisman, 1985; Ragusa et al., 1992).
Red blood cell transfusion and iron overload
Regular RBC transfusions have proved to be efficacious in the treatment of Î²-thalassemia by nullifying the complications of anaemia and compensatory bone marrow (BM) expansion. However, thalassaemias are also complicated by physiological iron overload which gets exacerbated by blood transfusion and causes various endocrine diseases, liver cirrhosis, cardiac failure and also death (Engle, 1964). Complemented with iron-chelating therapy (e.g., deferoxamine) for iron overload, the prognosis of thalassemia major has become dramatic (Olivieri and Brittenham, 1997).Â Â Recently, the mechanism of iron overload in the absence of transfusion in thalassaemia has been unraveled by Tanno et al. (2007) who observed that the overproduction of the protein GDF15 suppresses the production of the liver protein, hepcidin in thalassaemia patients which eventually leads to an increase in the uptake of dietary iron in the gut. This information could translate into new diagnostic and therapeutic tools in the future.
6. Critical review of thalassemias : (ii) Clinical management therapies
Î²-thalassaemia syndromes are the most common genetic diseases worldwide. Improvements in treatment strategies have resulted in good prognosis. Yet, disease- and treatment-related complications get exacerbated over time, increasing morbidity and curtailing life expectancy of the patients. Currently, the only curative treatment available for thalassaemia is stem cell transplantation (SCT) (Gaziev et al., 2008) which is a gold standard in treating the disease. Many challenges exist for transplantation therapy including graft versus host disease (GVHD), rejection of the donated stem cells, and infections while a major limitation for SCT is finding HLA-matched blood-related donors viz., siblings. Currently available high-resolution HLA-typing could minimise rejection and GVHD by matching major as well as minor HLA antigens (Gaziev et al., 2008). The advanced techniques of HLA-typing can also identify unrelated but suitable voluntary donors.
Intermittent red blood cell transfusion is the recommended mode of treatment for people who have moderate or severe thalassaemias. Î²-thalassemia major, or Cooley's anaemia require regular blood transfusions.
Emerging Gene Therapies
Gene therapy for treatment of thalassaemia is still evolving. Research is focussed on finding a potential treatment of Î² -thalassemia based on globin gene transfer. One of the aims of the genetic research is to trigger the production of HbF in adults to make up for the lack of healthy adult haemoglobin. The molecular mechanisms that initiate the change in gene expression during the switch from foetal (HbF) to adult (HbA) have been partially elucidated. Several chemical compounds able to reactivate HbF synthesis in vitro and in vivo in adult bone marrow have been identified (Testa, 2009). Induction of HbF to treat thalassaemia is a novel therapeutic strategy especially for those patients who are resistant to conventional therapy that is, regular blood transfusions and chelation therapy (Gambari, 2010).
Chemical inducers of foetal haemoglobin
In view of the fact that gene therapy could be inaccessible to many because of biological/genetic as well as economic constraints (Gambari, 2010), chemical inducers are being extensively studied. Hydroxyurea has already been used as HbF inducer in both moderate and severe forms of Î²-thalassaemia (Testa, 2009). Some of the potential inducers of HbF are histone deacetylase (HDAC) inhibitors, DNA-binding drugs and inhibitors of the mTOR pathway (Gambari and Fibach, 2007). Also, according to Gambari and Fibach (2007) chemical inducers need to be used with caution since many of those used so far were potentially cytotoxic.
Erythropoietin suppression of apoptosis
Accelerated apoptosis has been observed in the erythroid progenitors of patients with Î²-thalassaemia major (Silva et al., 1996). The hormone erythropoietin (Epo), which is the principal regulator of red blood cell production, is known to interact with high-affinity receptors on the surface of erythroid progenitor cells and promote cell viability. Epo has been shown to repress apoptosis via Bcl-XL and Bcl-2 during proliferation and differentiation of erythroid progenitors (Silva et al., 1996). Hence, recombinant human erythropoietin (rHuEpo) could have potential application in the treatment of transfusion-dependent thalassaemia patients as it promotes the differentiation and proliferation of erythroid cells, and stimulates the production of HbF (Makis et al., 2001).
Inherited haemoglobinopathies including sickle cell disease and thalassaemias result from genetic abnormalities in the synthesis of globin protein chains. SCD is caused by structural defects in the haemoglobin molecule while thalassaemias occur due to reduced or absent globin chain. Only bone marrow or haematopoietic stem cell transplantation can cure patients with either disease.
Clinical management of SCD generally involves supportive therapy consisting of pain relief, fluids and antibiotics, and folic acid supplements. Cases with severe complications such as stroke, acute chest syndrome or frequent painful sickling crises are treated with hydroxyurea. Intermittent red cell transfusion is administered to most patients, pre-surgery and in specific cases of severe complications.
The only cure available currently for Î²-thalassaemia major is afforded by haematopoietic stem cell transplantation from a compatible donor. Most thalassaemia patients require regular transfusions of red cells and all patients need iron chelation therapy to overcome iron overload.Â Â
Adams R, 2003, 'Haemoglobinopathies', Haematology (Am Soc Haematol Educ Program)
Adams R, McKie V, Brambilla D, et al., 1998, 'Stroke prevention trial in sickle cell
anaemia', Control Clin Trials 19:110- 129.
Andrews NC, 1999, 'Disorders of iron metabolism', N Engl J Med, 341:1986-1995.
Andrews NC, 2008, 'Forging a field: the golden age of iron biology,' Blood, 112(2):
Anstey NM, Russel B, Yeo TW et al., 2009, 'The pathophysiology of vivax malaria',
Trends Parasitol., 25(5):220-227.
Aul C, Bowen DT & Yoshida Y, 1998, 'Pathogenesis, etiology, and epidemiology of
myelodysplastic syndromes', Haematologica, 83(1): 71-86.
Ballas SK, 1998, 'Sickle cell disease: clinical management', Bailliere's Clinical
Â Â Â Â Â Â Haematology, 11 (1): 185-214.
Ballas SK, 2002, 'Sickle cell anaemia: progress in pathogenesis and treatment', Drugs,
Bertero MT & Caligaris-Cappio F, 1997, 'Anemia of chronic disorders in systemic
autoimmune disease', Haematologica, 82(3):375-81.
Bessman JD, Gilmer PR & Gardner FH, 1983, 'Improved classification of anemias by
MCV and RDW', Am J Clin Pathol 80:322-326.
Beutler E, Gelbart T, Lee P, et al., 2000, 'Molecular characterisation of a case of
Atransferrinemia', Blood, 96:4071-4074.
Beutler E & Waalen J, 2006, 'The definition of anemia: what is the lower limit of
normal of the blood hemoglobin concentration?', Blood, 107(5): 1747-1750.
Bottomley SS, 2006, 'Congenital sideroblastic anemias', Curr Hematol Rep., 5(1):41-49.
Bunn HF, 1997, 'Pathogenesis and treatment of sickle cell disease', N Engl J
Â Â Â Â Â Â Med.337(11):762-769.
Castro O, 1996, 'Systemic fat embolism and pulmonary hypertension in sickle cell
Disease', Hematol Oncol Clin North Am. 10(6):1289-1303.
Centis F, Tabellini L, Lucarelli G, et al., 2000, 'The importance of erythroid expansion in
determining the extent of apoptosis in erythroid precursors in patients with beta-
thalassaemia major', Blood, 96:3624-3629
Chulilla JAM, ColÃ¡s MSR & MartÃn MG, 2009, 'Classification of anemia for
gastroenterologists', World J Gastroenterol. 15(37): 4627-4637.
Claster S and Vichinsky, EP, 2003, 'Managing sickle cell disease', BMJ,327:1151-
Cohen AR, 1987, 'Management of iron overload in the paediatric patient', Haematol
Oncol Clin North Am., 521-544.
Connes P, Hue O, Tripette J et al., 2008, 'Blood rheology abnormalities and vascular cell
adhesion mechanisms in sickle cell trait carriers during exercise', Clinical
Hemorheology & Microcirculation, 39(1-4): 179-184.
Creary M, Williamson D, & Kulkarni R, 2007, 'Sickle cell disease: current activities,
public health implications, and future directions', J Women's Health, 16(5):575-582.
Distenfeld A & Woermann U, 2009, 'Sickle Cell Anemia', Accessed 15 February 2010
Dugdale DC, 2008, 'Megaloblastic anemia', Medline Plus, Accessed 28 Jan 2010Â Â Â Â
Engle MA, Erlandson M & Smith CH, 1964, 'Late cardiac complications of chronic,
severe, refractory anaemia with haemochromatosis', Circulation, 30:698-705.
Fleming MD. 2002. 'The genetics of inherited sideroblastic anemias', Semin Hematol. Â
Gambari R, 2010, 'Foetal haemoglobin inducers and thalassaemia: novel achievements',
Blood Transfus. 8(1): 5-7.
Gambari R & Fibach E, 2007, 'Medicinal chemistry of foetal haemoglobin inducers for
treatment of beta-thalassaemia', Curr Med Chem.14:199-212.
Gaziev J, Sodani P & Lucarelli C, 2008, 'Haematopoietic stem cell transplantation in
thalassaemia', Bone Marrow Transplantation, 42, S41.
Gilman JG & Huisman THJ, 1985, A sequence variation associated with elevated
foetal GÎ³globin production. Blood 66:783-787.
Gladwin MT & Kato GJ, 2005, 'Cardiopulmonary complications of sickle cell disease:
role of nitric oxide and hemolytic anemia', Haematology (Am Soc Hematol Educ
Â Â Â Â Â Â Program), pp 51-57.
Goldberg MA, Brugnara C, Dover GJ et al., 1990, 'Treatment of sickle cell anaemia with
Hydroxyurea and erythropoietin', NEJM, 323(6): 366-372.
Haas JD & Brownlie T, 2001, 'Iron deficiency and reduced work capacity: a critical
review of the research to determine a causal relationship', J Nutr., 131(2 Suppl):
Halterman JS, Kaczorowski JM, Aligne CA et al., 2001, 'Iron deficiency and cognitive
achievement among school-aged children and adolescents in the United States',
Pediatrics, 107: 1381-1386.Â Â
Hankins J, Jeng M, Harris S, et al., 2005, 'Chronic transfusion therapy for children with
sickle cell disease and recurrent acute chest syndrome', J Paediatr Haematol Oncol
27:158 - 161.
Herrick JB, 1910, 'Peculiar elongated and sickle-shaped red corpuscles in a case of
severe anemia', Arch Intern Med.6:517-521.
Hershko C & Skikne B, 2009, 'Pathogenesis and management of iron deficiency
anaemia: Emerging role of Celiac disease, Helicobacter pylori, and autoimmune
gastritis', Seminars in Hematology, 46 (4): 339-350.
Iolascon A, De Falco L. & Beaumont C, 2009, 'Molecular basis of inherited microcytic
anemia due to defects in iron acquisition or heme synthesis', Haematologica 94(3):
Jison ML, Munson PJ, Barb JJ et al., 2004, 'Blood mononuclear cell gene expression
profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell
disease', Blood, 104(1): 270-280. Â Â Â Â
Killip S, Bennett JM & Chambers MD, 2008, 'Iron deficiency anemia', American Family
Physician, 75(5): 671-678.
Kohgo Y, Ikuta K, Ohtake T. et al., 2008, 'Body iron metabolism and pathophysiology of
iron overload', Int J Hematol. 88(1): 7-15.
Krantz SB, 1994, 'Pathogenesis and treatment of the anemia of chronic disease', Am J
Â Â Â Â Â Â Med Sci.,307(5): 353-359.
Krishnamurtiâ€Œ L, 2007, 'Hematopoietic cell transplantation for sickle cell disease: state of
the art', Expert Opinion on Biological Therapy, 7(2): 161-172.
Josephson CD, Su LL, Hillyer KL, et al., 2007, 'Transfusion in the Patient With Sickle
Cell Disease: A Critical Review of the Literature and Transfusion Guidelines',
Transfusion Medicine Reviews, 21(2): 118-133.
MakisAC, ChaliasosN, Hatzimichael EC et al., 2001, 'Recombinant human
erythropoietin therapy in a transfusion-dependent Î²-thalassaemia major patient',
Annals of Haematology, 80(8):492-495.
Means RT Jr., 1996, 'Advancement in the anemia of chronic disease: A cytokine-
mediated anemia', Stem Cells, 13(1): 32-37.
Means RT Jr., 2003, 'Recent developments in the anemia of chronic disease', Current
Â Â Â Â Â Â Hematology Reports, 2(2):116-121.
Miller S, Rao S, Dunn K, et al., 1995, 'Priapism in children with sickle cell disease', J
Â Â Â Â Â Â Urol, 154:844- 847.
Mims MP, Guan Y, Pospisilova D, et al., 2005, 'Identification of a human mutation of
DMT1 in a patient with microcytic anemia and iron overload', Blood,105:1337-
MuÃ±oz M, Villar I & GarcÃa-Erce JA, 2009, 'An update on iron physiology', World J
Gastroenterol, 15(37): 4617-4626.
Nadkarni A, Gorakshakar AC, Lu CY, et al., 2001, 'Molecular pathogenesis and clinical
variability of Î²-thalassaemia syndromes among Indians', American Journal of
Olivieri NF & Brittenham GM, 1997, 'Iron-chelating therapy and the treatment of
Â Â Â Â Â Â thalassaemia', Blood, 89(3): 739-761
Pauling L, Itano HA, Singer SJ, et al., 1949,Â 'Sickle cell anemia: a molecular
disease', Science, 110(2865):543-548.
Quigley JG, Yang Z, Worthington MT, et al. 2004, 'Identification of a human heme
exporter that is essential for erythropoiesis', Cell, 118:757-766.
Ragusa A, Lambardo M, Beldjord C, et al., 1992, 'Genetic epidemiology of Î²-
thalassaemia in Sicily: do sequences 58 to the GÎ³ gene and 58 to the Î² gene interact to
enhance HbF expression in Î² -thalassemia?', Am J Hematol, 40:199-206.
Richardson M, 2007, 'Microcytic anemia', Pediatrics in Review, 28:5-14.
Rifikind S, Waisman J, Thompson R, et al., 1979, 'RBC exchange pheresis for priapism
in sickle cell disease', JAMA, 242:2317 - 2318.
Rodgers GP, Noguchi CT, Schechter AN, 1985, 'Irreversibly sickled erythrocytes in
sickle cell anemia: A quantitative reappraisal', Am J Hematol., 20(1): 17-23.
Rodgers GP, Dover GJ, Uyesaka N, et al., 1993, 'Augmention by erythropoietin of the
fetal-hemoglobin response to hydroxyurea in sickle cell disease', NEJM, 328(2): 73-
Rosenfeld C & List A, 2000, 'A hypothesis for the pathogenesis of myelodysplastic
syndromes: implications for new therapies', Leukemia, 14(1): 2-8.
Ru YX, Mao BY, Zhang FK et al., 2009, 'Invasion of erythroblasts by Plasmodium
vivax: A new mechanism contributing to malarial anaemia', Ultrastruct. Pathol.,
Shemin, D. & Rittenberg D, 1946, 'The life span of the human red blood cell', J Biol
Chem, 166: 627-636.
Siah CW, Ombiga J, Adams LA, et al., 2006, 'Normal iron metabolism and the
pathophysiology of iron overload disorders', Clin Biochem Rev. 27:5-16.
Silva M, Grillot D, Benito A, et al., 1996, Erythropoietin can promote erythroid
progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood,
Sokol RJ, Booker DJ & Stamps R, 1992, 'The pathology of autoimmune haemolytic
anaemia', J Clin Pathol., 45: 1047-1052.
Spivak, JL, 2002, 'Iron and the anemia of chronic disease', Oncology, 16(9 Suppl 10):25-
Spritz RA & Forget BG, 1983, 'The thalassemias: molecular mechanisms of human
genetic disease', Am J Hum Genet., 35:333-361.
Steinberg MH & Rodgers GP, 2001, 'Pharmacologic modulation of foetal haemoglobin',
Styles LA & Vichinsky E, 1994, 'Effects of a long-term transfusion regimen on sickle
cell- related illnesses', J Pediatr., 125:909-911.
Tanno T, Bhanu NV, Oneal PA et al., 2007, 'High levels of GDF15 in thalassemia
suppress expression of the iron regulatory protein hepcidin', Nature
Medicine, 13:1096 - 1101.
Tefferi A, 2003, 'Anaemia in adults: a contemporary approach to diagnosis', Mayo ClinÂ
Testa U, 2009, 'Fetal hemoglobin chemical inducers for treatment ofÂ
Haemoglobinopathies', Ann Hematol. 88:505-528.
Thein SL, 1993, 'Î²- Thalassaemia'. In: Higgs DR & Weatherall DA, editors, Bailliere's
clinical haematology: the hemoglobinopathis, Vol 6, Bailliere Tindall, London,
Tischkowitz MD & Hodgson SV, 2003, 'Fanconi anaemia', J Med Genet 2003;40:1-10
Tuck S, James C, Brewster E, et al., 1987, 'Prophylactic blood transfusions in maternal
sickle cell syndromes', Br J Obstet Gynaecol., 94:121 - 125.
Walter PB, Harmatz P & Vichinsky E, 2009, 'Iron metabolism and iron chelation in
sickle cell disease', Acta Haematol., 122(2-3):174-183.
Weatherall DJ, 1969, 'The genetics of the thalassaemias', British Medical Bulletin, 25(1):
Weatherall DJ, 1996, 'The molecular basis for phenotypic variability of the common
thalassaemias', Mol Med Today 1:15-20.Â
Weatherall DJ, 1997a, 'ABC of clinical haematology. The hereditary anaemias', BMJ
Weatherall DJ, 1997b, 'Fortnightly review: the thalassaemias', BMJ, 314(7095):1675-
WHO (1968), Nutritional anaemias. Report of a WHO scientific group. World Health
Organ Tech Rep Ser. 1968;405:5-37.
Wun T, 2001, 'The role of inflammation and leukocytes in the pathogenesis of sickle
cell disease', Hematology, 5(5): 403-412.